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Aflibercept targets vascular endothelial growth factor. The present study involved assess-
ing the efficacy, safety and pharmacokinetics of aflibercept plus 5- fluorouracil/levofoli-
nate/irinotecan (FOLFIRI) as a second- line treatment for metastatic colorectal cancer 
(mCRC) in Japanese patients. Aflibercept (4 mg/kg) plus FOLFIRI was administered every 
2 weeks in 62 patients with mCRC until disease progression, unacceptable toxicity or pa-
tient withdrawal. Tumors were imaged every 6 weeks. The primary endpoint was objective 
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response rate (ORR); secondary endpoints were progression- free survival, overall sur-
vival, safety, and pharmacokinetics of aflibercept, irinotecan and 5- fluorouracil. A total 
of 60 patients were evaluated for ORR; 50 had received prior bevacizumab. The ORR 
was 8.3% (95% confidence interval [CI]: 1.3%- 15.3%), and the disease control rate (DCR) 
was 80.0% (69.9%- 90.1%). The median progression- free survival was 5.42 months 
(4.14- 6.70 months) and the median overall survival was 15.59 months (11.20- 
19.81 months). No treatment- related deaths were observed, and no significant drug- 
drug interactions were found. The most common treatment- emergent adverse events 
were neutropenia and decreased appetite. Free aflibercept had a mean maximum con-
centration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) 
and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial 
growth factor had a clearance of 0.162 L/d (9%) (N = 62). Aflibercept did not signifi-
cantly affect the pharmacokinetics of irinotecan or 5- fluorouracil: The clearance was 
11.1 L/h/m2 (28%) for irinotecan and, at steady state, 72.6 L/h/m2 (56%) for 5- fluorouracil 
(N = 10). Adding aflibercept to FOLFIRI was shown to be beneficial and well- tolerated in 
Japanese patients with mCRC. ClinicalTrials.gov Identifier: NCT01882868.
K E Y WO RD S
aflibercept, angiogenesis inhibitors, colorectal neoplasms, neoplasm metastasis, vascular 
endothelial growth factor A
1  | INTRODUCTION
Colorectal cancer is the third most commonly occurring cancer 
worldwide and the second leading cause of cancer- related deaths.1 
In Japan, it is the most commonly occurring cancer in both sexes 
combined.2,3 The 5- year relative survival rate for metastatic colorec-
tal cancer (mCRC) is approximately 12%- 13%.4 Thus, it is important 
to develop new, more effective therapies.
Vascular endothelial growth factor (VEGF) is overexpressed in 
primary colon tumors that have metastasized compared to those that 
have not.5 Furthermore, high VEGF expression predicts poor relapse- 
free and overall survival of individuals with colorectal cancer.6 For 
this reason, VEGF has in recent years become a target for anti–can-
cer therapies, in combination with standard chemotherapy regimens 
folinic acid/5- fluorouracil (5- FU)/oxaliplatin (FOLFOX), FOLFOX/
irinotecan (FOLFOXIRI) or 5- FU/levofolinate/irinotecan (FOLFIRI). 
One anti–VEGF agent, bevacizumab, specifically blocks VEGF- A and, 
in combination with FOLFOX,7 FOLFOXIRI8,9 or FOLFIRI,10 has been 
shown to increase survival of patients with mCRC.
Aflibercept, also known as VEGF- trap or ziv- aflibercept, is a rel-
atively new anti–VEGF agent.11 It is a recombinant fusion protein 
containing portions of the extracellular domains of human VEGF re-
ceptors 1 and 2. Unlike bevacizumab, which binds only to VEGF- A, 
aflibercept binds to VEGF- A, VEGF- B and placental growth factor, 
thus blocking their downstream activity.
Several clinical trials have demonstrated the relative safety and 
efficacy of aflibercept plus FOLFIRI. The largest trial to date was an 
international randomized double- blind phase III study conducted 
outside of Japan (VELOUR study [NCT00561470]),12 which consisted 
of 1226 patients with mCRC who had previously received oxalipla-
tin. Aflibercept plus FOLFIRI significantly improved both overall sur-
vival (OS; 13.50 vs 12.06 months, P = .0032) and progression- free 
survival (PFS; 6.90 vs 4.67 months, P = .0001) compared to placebo 
plus FOLFIRI. Likewise, in a recently published randomized Phase 
III study of patients from the Asia- Pacific region, aflibercept plus 
FOLFIRI improved both OS (14.59 vs 11.93 months, hazard ratio: 
.794) and PFS (6.93 vs 5.59 months, hazard ratio: .629) compared to 
placebo plus FOLFIRI (NCT01661270).13 A phase I dose- escalation 
study of aflibercept plus FOLFIRI (NCT00921661)14 was conducted 
in Japanese patients with mCRC. No dose- limiting toxicities or major 
safety issues were observed for 4 mg/kg aflibercept, the standard 
dose.
The objectives of the current phase II study were to assess 
the efficacy, safety and pharmacokinetics (PK) of aflibercept plus 
FOLFIRI as a second- line treatment for mCRC in Japanese patients.
2  | METHODS
2.1 | Patients
Inclusion criteria were: histologically or cytologically proven adeno-
carcinoma of the colon or rectum; measurable disease, per Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1; inoperable 
metastatic disease; 1 prior chemotherapeutic, oxaliplatin- containing 
regimen for metastatic disease, during which or within 6 months 
after completion of which the disease progressed or patients 
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relapsed; Eastern Cooperative Oncology Group performance sta-
tus of 0 or 1; adequate organ function; and signed, dated informed 
consent. Exclusion criteria included active infectious disease, gas-
trointestinal ulcer, bleeding, urine protein- creatinine ratio >1, and 
uridine- 5- diphospho- glucuronosyltransferase 1A1 (UGT1A1) geno-
type of *6/*6, *28/*28 or *6/*28.
2.2 | Study design
This was a prospective, multicenter, open- label, single- arm study 
(Figure 1). All patients received the following treatment regimen once 
every 2 weeks: aflibercept (4 mg/kg) over 1- 2 hours by intravenous 
(i.v.) infusion; then levofolinate (200 mg/m2) over 120 ± 20 minutes, 
plus irinotecan (180 mg/m2) over 90 ± 15 minutes, simultaneously 
by i.v. infusion; then 5- FU (400 mg/m2) as a bolus over 2- 4 minutes; 
and then 5- FU (2400 mg/m2) over 41- 46 hours by continuous i.v. in-
fusion. Treatment was given until disease progression, unacceptable 
toxicity or patient withdrawal.
The primary endpoint was objective response rate (ORR). 
Secondary endpoints were PFS, OS, safety and PK.
2.3 | Efficacy assessments
Tumors were imaged every 6 ± 1 weeks and at the end- of- treatment 
visit 30 ± 3 days after the last study treatment. In the post–treatment 
follow- up period, tumors were imaged every 6 ± 1 weeks until disease 
progression. Survival status was determined every 2 months. ORR was 
defined as the percentage of patients with either a complete response 
(CR) or partial response (PR) to study treatment, determined based on 
tumor assessment by an independent radiological review committee 
(IRRC) using RECIST version 1.1 criteria. PFS was defined as the time 
interval from the first study treatment administration to either the first 
observation of radiologically documented disease progression, deter-
mined based on tumor assessment by the IRRC, or death due to any 
cause, whichever came first. OS was defined as the time interval from 
the first study treatment administration to death due to any cause.
In an exploratory analysis, ORR, PFS and OS were compared in pa-
tients with mutated KRAS (exon 2) vs those with wild- type KRAS and 
in patients with left- sided primary tumors (descending colon, sigmoid 
colon, rectosigmoid colon and/or rectum) vs those with right- sided 
primary tumors (caecum, ascending colon and/or transverse colon).
F IGURE  1 A, Study design. This prospective, multicenter, open- label, single- arm study consisted of a baseline period, a treatment period 
and a post–treatment follow- up period. During the follow- up period, tumors were imaged every 6 ± 1 wk until disease progression. (a) For 
subjects under Vitamin K antagonist therapy. (b) Before infusion, 1, 4 and 24 h in cycle 1 and before infusion in cycles 2 and 3. (c) Before 
infusion in cycles 1 and 3. B, Flow chart of patient participation
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2.4 | Safety assessments
Safety assessments were performed as shown in Figure 1 and in-
cluded physical examination, evaluation of laboratory data and 
assessment of adverse events. Laboratory safety tests were per-
formed at baseline, at every visit before treatment administration 
and at the end- of- treatment visit, and included hematology, bio-
chemistry, urinalysis, coagulation and any other tests as clinically in-
dicated. Laboratory abnormalities were recorded as adverse events 
only if they led to study treatment discontinuation or modification 
(eg, dose reduction, cycle delay or omission) and/or were serious (ie, 
were life- threatening and/or resulted in hospitalization, disability 
and death). Adverse events assessed included treatment- emergent 
adverse events (TEAE), serious adverse events and death.
For immunogenicity evaluation, blood samples were col-
lected before aflibercept infusion in treatment cycles 1 and 3, at 
30 ± 3 days and 90 ± 7 days after the last aflibercept infusion, and in 
cases of infusion- related allergic reaction (Grade ≥ 2) or proteinuria 
(>3.5 g/24 hours or of renal origin associated with hematuria). The 
presence of anti–aflibercept antibodies was evaluated in serum using 
a validated non–quantitative titer- based bridging immunoassay. If the 
result was positive, then the presence of aflibercept- neutralizing an-
tibodies was evaluated using a non–quantitative competitive ligand- 
binding assay.
2.5 | Population pharmacokinetics
A population PK approach was used to estimate individual PK param-
eters for free and VEGF- bound aflibercept in all 62 patients. Blood 
samples were obtained during treatment cycle 1: pre- treatment, be-
fore the end of infusion (EOI) of aflibercept (1 hour), and 3, 23 and 
335 hours (Day 14) after the EOI of aflibercept. Blood samples were 
also obtained pre- dose of every odd- numbered cycle, and 30 and 
90 days after the last administration of aflibercept.
Plasma concentrations were measured by validated enzyme- 
linked immunosorbent assays. Concentrations of VEGF- bound 
Screened for eligibility (i.e
signed informed, consent) (n = 68)
Enrollment
Registered (n = 62)
?Received study treatment (n = 62)
?Did not receive study treatment (n = 0)
Excluded (n = 6)  :
?Did not meet inclusion
    criteria (n = 6)
?Other reasons (n = 0)
Treatment
?Discontinued study treatment (n = 62):
?Disease progression (n = 45)
?Adverse event (n = 11)
?Request to undergo surgical operation of an
operable tumor (n = 4)
?Receiving other therapy (n = 2)
Follow-up
?Analyzed (n = 60 for ORR; n = 62 for PFS, OS, and safety)
?Excluded from analysis (n = 2 for ORR; n = 0 for PFS, OS,
  and safety):
?No measurable target or non–target lesion (n = 1)
?Only non-target lesions at baseline (n = 1)
Analysis
(B)
F IGURE  1   continued
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aflibercept were expressed as the free aflibercept equivalent by 
multiplying by 0.717, the ratio of the molecular weights of free and 
VEGF- bound aflibercept. The lower limits of quantification (LLOQ) 
were 15.6 and (adjusted) 31.5 ng/mL, respectively.
The PK parameters were maximum concentration (Cmax), area 
under the curve over the dosing interval (AUC0-14 day), total body 
clearance (CL) and volume of distribution at steady state (Vss) for free 
aflibercept, and CL for VEGF- bound aflibercept.
2.6 | Non–compartmental pharmacokinetics
Pharmacokinetics parameters were calculated for irinotecan, its 
active metabolite SN- 38, and 5- FU in the first 10 patients by non–
compartmental analysis (PKDMS Version 2 running with WinNonLin 
Professional, Version 5.2.1, PharSight, Raleigh- Durham, NC, USA). 
Blood samples for irinotecan and SN- 38 were obtained before afliber-
cept infusion, just before EOI of irinotecan (1.5 hours), and 2, 4.5 and 
23 hours after the start of irinotecan infusion during cycle 1. Blood 
samples for 5- FU were obtained before the start of aflibercept infu-
sion and 2.5, 21 and 45 hours after the start of 5- FU infusion during 
cycle 1. Concentrations were measured using validated electrospray 
liquid chromatography tandem mass spectrometry for irinotecan, 
SN- 38 and 5- FU (LLOQ: 10.0, 1.0 and 5.0 ng/mL, respectively).
TABLE  1 Patient and disease characteristics at baseline
Characteristic Value (N = 60)
Age in years
Mean (SD) 61.6 (9.8)
Median 62.5
Min:Max 39:78
Age group in years (n [%])
<65 33 (55.0)
≥65 but <75 24 (40.0)
≥75 3 (5.0)
Sex (n [%])
Male 34 (56.7)
Female 26 (43.3)
Race (n [%])
Asian/Oriental 60 (100)
Other 0 (0)
ECOG performance status (n [%])
0 40 (66.7)
1 20 (33.3)
Body weight in kg
Mean (SD) 59.67 (10.48)
Median 57.70
Min:Max 39.8:86.8
Body surface area in m2
Mean (SD) 1.626 (0.167)
Median 1.613
Min:Max 1.29:1.99
Prior hypertension (n [%])
Yes 31 (51.7)
No 29 (48.3)
UGT1A genotype (n [%])a
Wild- type
*1/*1 20(60.6)
Heterozygous
*1/*28 4 (12.1)
*1/*6 9 (27.3)
Complex heterozygous
*6/*28 0
Homozygous
*28/*28 0
*6/*6 0
Primary tumor location (n [%])
Left (descending colon, sigmoid, 
rectosigmoid, rectum)
45 (75.0)
Right (caecum, ascending colon, 
transverse colon)
15 (25.0)
Histology type (n [%])
(Continues)
Characteristic Value (N = 60)
Adenocarcinoma 60 (100)
Histopathology
Well or moderately differentiated 55 (91.7)
Undifferentiated or poorly 
differentiated
2 (3.3)
Unknown 3 (5.0)
Number of metastatic organs
>1 36 (60.0)
1 24 (40.0)
Liver metastasis only (n [%])
Yes 9 (15.0)
No 51 (85.0)
Prior bevacizumab (n [%])
Yes 50 (83.3)
No 10 (16.7)
Prior adjuvant therapy (n [%])
Yes 8 (13.3)
No 52 (86.7)
Time from 1st diagnosis to 1st study treatment administration (mo)
Mean (SD) 18.79 (14.74)
Median 14.93
Min:Max 3.7:89.6
ECOG, Eastern Cooperative Oncology Group; UGT1A1, uridine- 5- 
diphospho- glucuronosyltransferase 1A1.
aN = 33. 
TABLE  1  (Continued)
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The PK parameters for irinotecan and SN- 38 were Cmax, time to 
reach Cmax(tmax), AUC until last quantifiable time point (AUClast), AUC 
extrapolated to infinity (AUC), terminal elimination half- life (t1/2z) and 
metabolic ratio based on molecular weight (Rmet). For irinotecan, CL 
and Vss were also estimated. For 5- FU, steady- state concentration 
during constant- rate infusion (Css) and clearance at steady state (CLss) 
were estimated.
2.7 | Statistical analysis
This study aimed to estimate the ORR in Japanese patients with 
mCRC at a certain precision. In prior studies of patients with mCRC 
treated in the second line with FOLFIRI or FOLFIRI plus aflibercept, 
ORR ranged from approximately 10% to 20%.10-17 If the ORR ob-
served in this study was in the same range, then 60 patients would 
provide precision (range of 95% CI) from 0.16 to 0.20.
The best objective response was summarized with descriptive 
statistics. ORR with its associated 95% CI was calculated using nor-
mal approximation based on the best objective response judged by 
the IRRC.
The median PFS, median OS, and their associated probability 
of survival at each time point and 95% CI were estimated using the 
Kaplan- Meier method. The time points were every 3 months, for a 
total of 15 months for PFS and 24 months for OS.
For each laboratory parameter, a patient was considered eval-
uable if ≥1 measurement was available on treatment. Laboratory 
toxicities were graded from 1 (least severe) to 5 per National 
Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI CTCAE) version 4.03 and were summarized as “all grades” or 
“Grade ≥3.” For patients with multiple occurrences of a particular 
laboratory parameter during the study treatment period, the max-
imum (worst) grade was used.
Treatment- emergent adverse events were adverse events re-
ported between the first study treatment infusion and 30 days after 
the last one. TEAE were summarized with respect to frequency 
and intensity/severity, as graded by the worst NCI CTCAE version 
4.03 criteria. All TEAE were coded using the Medical Dictionary for 
Regulatory Activities version 18.0.
2.8 | Ethical considerations
The study was conducted in accordance with the principles of the 
Declaration of Helsinki and in compliance with all international 
and Japanese laws, regulations and guidelines. All aspects of the 
study were approved by the independent ethics committee and 
institutional review board. Patients were fully informed of the 
study and provided written consent. The study was registered with 
ClinicalTrials.gov with the identifier NCT01882868.
3  | RESULTS
This study started when the first patient was enrolled in July 2013 and 
closed on the day of database lock in August 2015. Sixty- two patients 
from 19 clinical sites in Japan were enrolled. Two patients were not 
evaluable for ORR: one had neither a target nor a non–target lesion, 
F IGURE  2 Waterfall plot showing best objective response in 60 patients. CI, confidence interval; DCR, disease control rate; ORR, 
objective response rate; OS, overall survival; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease
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and one had only non–target lesions at baseline. The demographics and 
disease characteristics of the 60 evaluable patients appear in Table 1. 
Fifty evaluable patients (83.3%) had received prior bevacizumab.
As of the final database lock, all patients had discontinued study 
treatment (Figure 1). The median number of treatment cycles re-
ceived per patient was 8.0 (range: 1- 31), and the median duration of 
study treatment exposure was 21.8 weeks (range: 2- 73 weeks). The 
median relative dose intensities were 72% for aflibercept, 65% for 
irinotecan and 71% for 5- FU.
3.1 | Efficacy
Five of the 60 evaluable patients had PR and none had CR, resulting 
in an ORR of 8.3% (95% CI: 1.3%- 15.3%). In addition, 43 (71.7%) had 
F IGURE  3 Kaplan- Meier curve of 
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F IGURE  4 Kaplan- Meier curve of overall survival
.0
0
62
Number at risk
All
Symbol = Censor
All    
3
61
6
54
9
47
12
37
15
32
2718
24
21
8
24
2
.1
.2
.3
.4
.5
.6
.7
.8
.9
.0
K
ap
la
n-
M
ei
er
 e
st
im
at
e
Time (months)
     |  1039DENDA Et Al.
stable disease, for an overall DCR of 80.0% (95% CI: 69.9%- 90.1%; 
see also Figure 2).
The other efficacy endpoints were evaluated for all 62 patients. 
The median PFS was 5.42 months (95% CI: 4.14- 6.70; Figure 3). As 
of the last tumor assessment, 47 (75.8%) patients had documented 
disease progression, 11 (17.7%) had died without disease progres-
sion and 4 (6.5%) had no disease progression. The median OS was 
15.59 months (range: 11.20- 19.81 months; Figure 4). As of the final 
cutoff date, 21 (33.9%) patients had survived. The 2- year survival 
rate was 28.2% (95% CI: 14.8%- 41.6%).
Of the 62 patients, 26 had mutant KRAS, 29 had wild- type KRAS 
and 7 had unknown KRAS status. Forty- seven patients had a left- 
sided primary tumor and 15 had a right- sided tumor. The ORR, PFS 
and OS based on KRAS status and primary tumor location are shown 
in Table S1 and Figures S1 and S2.
After discontinuing the study treatment, 51 (82.3%) patients 
received ≥1 further anti–cancer therapy, including 39 (62.9%) who 
received further biologics/small molecules (cetuximab: 9 [14.5%]; 
bevacizumab: 9 [14.5%]; regorafenib: 15 [24.2%]; panitumumab: 10 
[16.1%]).
3.2 | Safety
Hematological abnormality occurred in most patients: leukope-
nia (87.1% of patients), neutropenia (85.5%), anemia (82.3%) and 
thrombocytopenia (62.9%) (Table 2). Of all clinical laboratory ab-
normalities assessed, an abnormal creatinine level was the most 
common, affecting 60 patients (96.8%). Proteinuria occurred in 
51 patients (82.3%); of these cases, 22 (43.1%) occurred in treat-
ment cycle 1.
All patients had ≥1 TEAE. Fifty- six patients (90.3%) had Grade 3 
or 4 TEAE; the most common TEAE were neutropenia, hypertension, 
diarrhea and decreased appetite (Table 3). Furthermore, 20 patients 
had ≥1 serious adverse event. Forty- one (66.1%) patients died due 
to disease progression, all >30 days after the last study treatment 
administration. No patients died as a result of treatment.
One patient was positive for anti–aflibercept antibodies at base-
line (and positive in the neutralizing antibody assay); however, all 
subsequent samples from this patient were negative.
3.3 | Pharmacokinetics
Population PK data (free and VEGF- bound aflibercept) and non–com-
partmental PK data (irinotecan, SN- 38 and 5- FU) appear in Table 4. 
Plasma concentrations for all 5 analytes are shown in Figure 5.
4  | DISCUSSION
This study examined the efficacy, safety and PK of aflibercept plus 
FOLFIRI in Japanese patients with mCRC that was refractory or in-
tolerant to a first- line oxaliplatin- containing regimen. The primary 
endpoint, ORR by the IRRC, was 8.3% (95% CI: 1.3%- 15.3%).
The ORR was lower than that in the VELOUR study (19.8%; 95% 
CI: 16.4%- 23.2%). Possible reasons for this discrepancy are differ-
ences between the study populations and the limited size of our 
study. Consistent with a lower ORR, the PFS in the current study 
was slightly shorter than that in the VELOUR study: 5.42 months 
(95% CI: 4.14- 6.70) vs 6.90 months (6.51- 7.20) overall.12 Based on 
these findings and the DCR of 80.0% (95% CI: 69.9%- 90.1%), adding 
TABLE  2 Clinical laboratory abnormalities
Clinical laboratory tests
Abnormalities, n (%)
All grades Grade ≥3
Hematological tests (N = 62)
Leukopenia 54 (87.1) 19 (30.6)
Neutropenia 53 (85.5) 39 (62.9)
Anemia 51 (82.3) 1 (1.6)
Thrombocytopenia 39 (62.9) 0
Liver and renal tests (N = 62)
ALT 35 (56.5) 3 (4.8)
AST 38 (61.3) 4 (6.5)
Alkaline phosphatase 45 (72.6) 3 (4.8)
Total bilirubin 20 (32.3) 2 (3.2)
Creatinine 60 (96.8) 1 (1.6)
Urine tests (N = 62)
Proteinuria 51 (82.3) 13 (21.0)
UPCR
≤1a 37 (59.7) –
>1, ≤2 10 (16.1) –
>2, ≤3 5 (8.1) –
>3 10 (16.1) –
Dipstick RBC
+ 16 (25.8) –
++ 9 (14.5) –
+++ 7 (11.3) –
++++ 1 (1.6) –
Metabolism tests (N = 62)
Hypoglycemia 1 (1.6) 0
Hyperglycemia 49 (79.0) 1 (1.6)
Hypoalbuminemia 51 (82.3) 2 (3.2)
Electrolyte tests (N = 62)
Hypocalcemia 11 (17.7) 0
Hypercalcemia 5 (8.1) 0
Hypokalemia 20 (32.3) 1 (1.6)
Hyperkalemia 17 (27.4) 0
Hyponatremia 25 (40.3) 2 (3.2)
Hypernatremia 5 (8.1) 0
Hypophosphatemia 21 (33.9) 4 (6.5)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; RBC, 
red blood cells; UPCR, urine protein- creatinine ratio.
aIncludes UPCR in the normal range of 0 to <0.15. 
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aflibercept to FOLFIRI yielded results consistent with those of the 
VELOUR study. The ORR and PFS were also comparable to those in 
the Asia- Pacific study13 (ORR = 8.3% [95% CI: 1.3%- 15.3%] vs 18% 
[13.3%- 23.5%] and PFS = 5.42 months [4.14- 6.70] vs 6.93 months 
[6.045- 7.655]).
The median OS of 15.59 months (95% CI: 11.20- 19.81) was sim-
ilar to the median OS in both the VELOUR study12 (13.50 months; 
95% CI: 12.52- 14.95) and the Asia- Pacific study13 (14.59 months; 
95% CI: 13.18- 16.46), with overlapping 95% CI. Neither the KRAS 
oncogene nor primary tumor sidedness significantly affected ORR, 
PFS or OS.
The safety profile was as expected of an anti–VEGF agent and 
was comparable to that observed in the VELOUR study. Together, 
the TEAE represent an enhancement of the toxicity profile associ-
ated with usage of FOLFIRI. The absence of a sample positive for 
anti–aflibercept antibodies post–treatment suggests that IV admin-
istration of 4 mg/kg aflibercept confers no immunogenicity in pa-
tients with mCRC.
The PK values of free aflibercept were comparable to those 
in previous studies for Chinese patients.18 Adding aflibercept to 
FOLFIRI did not significantly affect the PK of irinotecan, SN- 38 or 
5- fluorouracil: the PK values of these FOLFIRI components were 
comparable between the current study, in which aflibercept was 
added, and published studies in which it was not. For example, the 
clearance of irinotecan in the current study was similar to the values 
in the Gupta et al19 study and in the Satoh et al20 study. The AUC for 
irinotecan and SN- 38 overlaps19 or is slightly high.20 The clearance 
of 5- FU in our study had a relatively large coefficient of variance 
TABLE  3 Most commonly reported treatment- emergent adverse 
events
Primary system organ class
n (%)
All grades Grade ≥3
Preferred term
 Any class 62 (100) 56 (90.3)
 Blood and lymphatic system 
disorders
46 (74.2) 38 (61.3)
Neutropenia 46 (74.2) 38 (61.3)
 Metabolism and nutrition 
disorders
47 (75.8) 10 (16.1)
Decreased appetite 46 (74.2) 8 (12.9)
 Nervous system disorders 18 (29.0) 0
Headache 7 (11.3) 0
 Vascular disorders 33 (53.2) 17 (27.4)
Hypertension 29 (46.8) 17 (27.4)
 Respiratory, thoracic, and 
mediastinal disorders
45 (72.6) 2 (3.2)
Epistaxis 25 (40.3) 0
Dysphonia 18 (29.0) 0
Cough 7 (11.3) 0
Hiccups 7 (11.3) 0
 Gastrointestinal disorders 56 (90.3) 18 (29.0)
Diarrhea 42 (67.7) 12 (19.4)
Nausea 36 (58.1) 2 (3.2)
Stomatitis 29 (46.8) 5 (8.1)
Vomiting 17 (27.4) 0
Constipation 10 (16.1) 0
Abdominal pain 9 (14.5) 0
 Skin and subcutaneous tissue 
disorders
44 (71.0) 1 (1.6)
Alopecia 30 (48.4) 0
Palmar- plantar erythro-
dysesthesia syndrome
8 (12.9) 0
 Rash 7 (11.3) 0
 Renal and urinary disorders 19 (30.6) 6 (9.7)
Proteinuria 19 (30.6) 6 (9.7)
 General disorders and 
administration site conditions
44 (71.0) 4 (6.5)
Fatigue 39 (62.9) 3 (4.8)
Pyrexia 13 (21.0) 0
TABLE  4 Summary of PK parameters in treatment cycle 1
PK parametersa Mean ± SD (CV%)
Free aflibercept
Cmax, μg/mL 73.2 ± 10.7 (15%)
AUC0-14 d, μg·day/mL 247 ± 41 (17%)
Clearance, L/d 0.805 ± 0.178 (22%)
Vss, L 6.20 ± 1.11 (18%)
VEGF- bound aflibercept
Clearance, L/d 0.162 ± 0.014 (9%)
Irinotecan
Cmax, ng/mL 2220 ± 528 (24%)
AUC, ng·h/mL 17 700 ± 6400 (36%)
t1/2z, h 5.19 ± 0.74 (14%)
Clearance, L/h/m2 11.1 ± 3.2 (28%)
Vss, L/m
2 55.7 ± 16.0 (29%)
SN- 38b
Cmax, ng/mL 32.2 ± 11.4 (36%)
AUC, ng·h/mL 341 ± 72 (21%)
t1/2z, h 10.3 ± 3.1 (30%)
5- FU
CLss, L/h/m
2 72.6 ± 40.4 (56%)
AUC0-14 d, area under the concentration vs time curve 0- 14 d post start of 
infusion; CLss, clearance at steady state; Cmax, maximum plasma concen-
tration observed; CV%, coefficient of variation; 5- FU, 5- fluorouracil; PK, 
pharmacokinetics; SD, standard deviation; t1/2z, terminal elimination half- 
life; Vss, volume of distribution at steady state.
aN = 62 for free and vascular endothelial growth factor- bound afliber-
cept. N = 10 for irinotecan, SN- 38 and 5- FU, for which a non–compart-
mental PK analysis was performed after a 1- h infusion of aflibercept 
(4 mg/kg). 
bRepresented 3% of irinotecan exposure. 
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F IGURE  5 Plasma concentrations 
of study drugs over time in treatment 
cycle 1. Blood samples were collected 
from 10 patients before treatment cycle 
1 and at various time points throughout 
cycle 1. Plasma concentrations of (A) 
free and vascular endothelial growth 
factor (VEGF)- bound aflibercept were 
determined using validated enzyme- 
linked immunosorbent assays. Plasma 
concentrations of (B) irinotecan, SN- 
38 and (C) 5- fluorouracil (5- FU) were 
determined using validated electrospray 
liquid chromatography tandem mass 
spectrometry
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(56%), consistent with studies showing that 5- FU plasma clearance is 
widely variable among patients (reviewed by Lee et al21). In previous 
population pharmacokinetic analyses, no clinically relevant drug- 
drug interactions between aflibercept and irinotecan or fluorouracil 
were found.22 Likewise, no significant drug- drug interactions were 
found in the current study.
A limitation of this study is its small sample size compared to 
that of the VELOUR study. In addition, unlike the VELOUR study, 
the current study had no control arm, so ability to compare the ORR 
results in the 2 studies is limited. Studies containing larger numbers 
of Japanese patients are needed to corroborate our findings.
In conclusion, adding aflibercept to FOLFIRI was shown to be 
beneficial and well- tolerated in Japanese patients with mCRC.
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